share_log

CUBEBIO Co., Ltd. Entered Into Terms Relating To A Potential Business Combination With Mountain Crest Acquisition Corp. V

CUBEBIO Co., Ltd. Entered Into Terms Relating To A Potential Business Combination With Mountain Crest Acquisition Corp. V

CUBEBIO Co., Ltd. 與 Mountain Crest Acquisition Corp. V 簽訂了與潛在業務合併相關的條款
Benzinga ·  05/02 21:14

Mountain Crest Acquisition Corp. V, a Delaware corporation ("Mountain Crest V"), that is a Nasdaq-listed (NASDAQ:MCAG) special purpose acquisition company ("SPAC"), and CUBEBIO Co., Ltd., a Korea-based company ("CUBEBIO"), which has an innovative technology that diagnoses cancer at an early stage using urine, today announced that the parties entered into a non-binding term sheet on April 26, 2024 for a proposed business combination through which CUBEBIO plans to become a public company with its securities listed on The Nasdaq Stock Market. Mountain Crest V is the fifth vehicle in the Mountain Crest family of SPACs, the management of which has successfully completed four prior SPAC business combinations.

特拉華州公司(“Mountain Crest V”)是一家在納斯達克上市(納斯達克股票代碼:MCAG)的特殊目的收購公司(“SPAC”)Mountain Crest Acquisition Corp. V.(“Mountain Crest V”)和總部位於韓國的公司(“CUBEBIO”)CubeBIO有限公司(“CUBEBIO”)今天宣佈,雙方簽訂了一份不具約束力的條款表。2024年4月26日,CUBEBIO計劃通過該合併成爲一家上市公司,其證券在納斯達克股票市場上市。Mountain Crest V是Mountain Crest系列SPAC中的第五款車輛,該公司的管理層已經成功完成了之前的四次SPAC業務合併。

Based on the non-binding term sheet, the pre-transaction equity value of CUBEBIO for the proposed business combination is $620 million, subject to adjustment depending on additional due diligence by Mountain Crest V and market conditions.

根據不具約束力的條款表,CUBEBIO在擬議業務合併中的交易前股權價值爲6.2億美元,可能會根據Mountain Crest V的額外盡職調查和市場狀況進行調整。

Global Fund LLC, a Washington D.C.-based advisory firm specializing in SPAC and DeSPAC transactions in the U.S., has been engaged by CUBEBIO to advise CUBEBIO in connection with the proposed business combination.

Global Fund LLC是一家總部位於華盛頓特區的專門從事美國SPAC和DesPac交易的諮詢公司,已受CUBEBIO聘請,爲CUBEBIO就擬議的業務合併向CUBEBIO提供建議。

Dr. Suying Liu, Chairman, CEO and CFO of Mountain Crest V commented, "CUBEBIO's innovative diagnostic technology for cancer detection and active commercialization with contract in place point to significant growth potential. We are excited to be partnering with CUBEBIO on this proposed business combination."

Mountain Crest V董事長、首席執行官兼首席財務官劉素英博士評論說:“CUBEBIO用於癌症檢測的創新診斷技術和已簽訂合同的積極商業化表明了巨大的增長潛力。我們很高興能與CUBEBIO合作進行這項擬議的業務合併。”

Eun-jong Choi, CEO of CUBEBIO emphasized, "We expect to execute a definitive merger agreement with Mountain Crest V, faithfully carry out the process for completing the business combination, and grow CUBEBIO into a global company by increasing corporate value."

CUBEBIO首席執行官崔恩鍾強調說:“我們希望與Mountain Crest V簽署最終合併協議,忠實地執行完成業務合併的流程,並通過提高企業價值將CUBEBIO發展成爲一家跨國公司。”

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論